Intravitreal Injection of Ziv-Aflibercept in the Treatment of Choroidal and Retinal Vascular Diseases Publisher



Hodjatjalali K¹ ; Mehravaran S² ; Faghihi H¹ ; Hashemi H¹ ; Kazemi P³ ; Rastad H^{3, 4}
Source: Journal of Current Ophthalmology Published:2017

Abstract

Purpose To investigate the short-term outcomes after intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. Methods Thirty-four eyes of 29 patients with age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO) received a single dose intravitreal injection of 0.05 ml ziv-aflibercept (1.25 mg). Visual acuity, spectral domain optical coherence tomography (SD-OCT) activity, and possible side effects were assessed before and at 1 week and 1 month after the intervention. Results At 1 month after treatment, mean central macular thickness (CMT) significantly decreased from 531.09 μm to 339.5 μm (P < 0.001), and no signs of side effects were observed in any subject. All patients responded to treatment in terms of reduction in CMT. The improvement in visual acuity was statistically non-significant. Conclusion Our findings suggest that a single dose intravitreal injection of ziv-aflibercept may have acceptable relative safety and efficacy in the treatment of patients with intraocular vascular disease. The trial was registered in the Iranian Registry of Clinical Trials (IRCT2015081723651N1). © 2017 Iranian Society of Ophthalmology